

THE VALUE OF LIPOCALIN-2 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Thesis

*Submitted for Partial Fulfillment of Master Degree (M.Sc) in
Physical Medicine, Rheumatology and Rehabilitation*

By

Talib Mohammed Hassan

M.B., Ch. B.

Supervised by

Prof. Dr. Nahid Mounir Sherif

*Professor and head of physical medicine, Rheumatology
and Rehabilitation department*

Faculty of Medicine - Ain Shams University

Prof. Dr. Neveen Mahmoud Taha Fouda

*Professor of physical medicine, Rheumatology and
Rehabilitation*

Faculty of Medicine - Ain Shams University

Assist. Prof. Dr. Soha Eldessouki Ibrahim

*Assistant Professor of physical medicine,
Rheumatology and Rehabilitation*

Faculty of Medicine - Ain Shams University

*Faculty of Medicine
Ain Shams University*

2016

List of Contents

<i>Title</i>	<i>Page No.</i>
List of Abbreviations.....	
List of Tables	
List of Figures	
Introduction	
Aim of the work	
<u>Review of Literature</u>	
• Systemic Lupus Erythematosus	
• Lupus Nephritis.....	
• Lipocalin-2	
Subjects and Methods	
Results	
Discussion	
Summary	
Conclusion.....	
Recommendations	
References	
Arabic Summary	--

List of Abbreviations

<i>Abb.</i>	<i>Full Term</i>
ACR	American College of Rheumatology
ANA	Anti nuclear antibody
Anti-Sm	Anti Smith antibody
APCs	Antigen presenting cells
AUC	Area Under the Curve
BUN	Blood urea nitrogen
C	Complement
CBC	Complete blood picture
CD	Cluster of differentiation
ds-DNA	Double stranded deoxyribonucleic acid
EBV	Ebstein Barr virus
ELISA	Enzyme linked immunosorbent assay
ESR	Erythrocyte sedimentation rate
ESRD	End stage renal disease
Fc	Fraction of crystallizable
GFR	Glomerular filtration rate
Hb	Heamoglobin
HLA	Human leucocytic antigen
IFN	Interferone
Ig	Immunoglobulin
IL	Interleukin
iNOS	Inducible nitric oxide synthase
LN	Lupus nephritis
MMF	Mycofenolate mofitel

<i>Abb.</i>	<i>Full Term</i>
MMP	Matrix metallopeptidase
NGAL	Neutrophil gelatinase associated lipocalin-2
NK	Natural killer
NO	Nitric axide
p value	Probability value
R	Pearson correlation coefficient
RBC	Red blood cell
RNA	Ribonucleic acind
ROC	Receiver operating characteristic
ROS	Reactive oxygen species
SD	Standard deviation
SLEDAI	Systemic lupus erythematosus disease activity index
SLICC/ACR-DI	Systemic lupus International Collaborating clinics/ American College of Rheumatology damage index.
TLR	Toll like receptor
TNF	Tumor necrosis factor
Upro/crea	Urinary protein/ creatinine ratio
UV	Ultra violet
WBCs	White blood cells
WHO	World Health Organization

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Genetic defects involved in immune complex clearance	10
Table (2):	Environmental factors that might play a role in the pathogenesis of SLE.....	13
Table (3):	Some auto-antibodies involved in the pathogenesis of SLE.	17
Table (4):	The 1997 revised ACR criteria for the classification of SLE	27
Table (5):	Clinical and Immunologic Criteria Used in the SLICC Classification Criteria.....	28
Table (6):	International Society of Nephrology/ Renal Pathology Society (ISN/ RPS) classification of nephritis.....	46
Table (7):	International Society of Nephrology/ Renal Pathology Society (ISN/ RPS) classification of nephritis.....	47
Table (8):	The SLE disease activity index (SLEDAI).....	75
Table (9):	Comparison between SLE patients and control group regards demographic data.	80
Table (10):	Clinical manifestation of SLE patients:.....	80
Table (11):	Disease activity scores and the laboratory parameters of SLE patients:	81
Table (12):	Comparison between SLE patients and control group as regards mean levels of urinary lipocalin-2:.....	83
Table (13):	Comparison between levels of serum lipocalin-2 in SLE patients and control group.....	85
Table (14):	Demographic data of SLE patients with nephritis (group I):.....	87
Table (15):	Disease activity scores and the laboratory parameters of group I:.....	89
Table (16):	Comparison of the mean levels of urinary lipocalin-2 and serum lipocalin-2 in group I patients and control group:	90

List of Tables (Cont...)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (17):	Demographic data of SLE patients without lupus nephritis group (II):	92
Table (18):	Disease activity scores and the laboratory parameters of group II:	94
Table (19):	Comparison of the mean levels of urinary lipocalin-2 and serum lipocalin-2 in group II patients and the control group.....	95
Table (20):	Comparison between group I and group II as regards demographic data.	97
Table (21):	Comparison between 2 groups as regards disease activity score and laboratory data.	99
Table (22):	Comparison between group I and group II as regards the levels of urinary and serum lipocalin-2:.....	101
Table (23):	Correlations of urinary lipocalin-2 with disease activity score SLEDAI and other labrotory parameters in group I:.....	104
Table (24):	Correlations of serum lipocalin-2 with disease activity scores and other labrotory parameters in group I:	108
Table (25):	Correlations of urinary lipocalin-2 with disease activity score and other labrotory parameters in group II.	110
Table (26):	Correlations of serum lipocalin-2 with disease activity score SLEDAI and other labrotory parameters in group II:	112

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Fig. (1):	The spiral of disease progression in SLE	7
Fig. (2):	Hypothetical pathways involved in the pathogenesis of SLE	8
Fig. (3):	General structure of an IgG antibody	16
Fig. (4):	B cell differentiation to autoantibody-producing cell	20
Fig. (5):	Schematic representation of the lipocalin fold	57
Fig. (6):	Comparison between the mean levels of urinary lipocalin-2 in SLE patients and controls.....	83
Fig. (7):	Comparison between the mean levels of serum lipocalin-2 in all SLE patients and controls.....	85
Fig. (8):	Comparison between group (I) and control as regards urinary lipocalin 2 (ng/ml).	91
Fig. (9):	Comparison between group (I) and control as regards serum lipocalin 2 (ng/ml).....	91
Fig. (10):	Comparison between group (II) and control as regards urinary lipocalin 2 (ng/ml).	96
Fig. (11):	Comparison between group (II) and control as regards serum lipocalin 2 (ng/ml).	96
Fig. (12):	Comparison between both groups as regards Total SLEDAI score.	100
Fig. (13):	Comparison between both groups as regards extra renal SLEDAI score.	100
Fig. (14):	Comparison between the mean levels of urinary lipocalin-2 in group I and group II.	102
Fig. (15):	Comparison between the mean levels of serum lipocalin-2 in group I and group II.	102
Fig. (16):	Positive significant correlation between urinary lipocalin 2 (ng/ml) and renal SLEDAI.....	105
Fig. (17):	Positive significant correlation between urinary lipocalin 2 (ng/ml) and total renal SLEDAI.....	105
Fig. (18):	Positive significant correlation between urinary lipocalin 2 (ng/ml) and BUN.....	106

List of Figures (Cont...)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Fig. (19):	Positive significant correlation between urinary lipocalin 2 (ng/ml) and serum creatinine.....	106
Fig. (20):	Positive significant correlation between urinary lipocalin 2 (ng/ml) and 24hr/urine protein.	107
Fig. (21):	Negative significant correlation between serum lipocalin 2 (ng/ml) and C4.	113
Fig. (22):	ROC curve analysis showing the diagnostic performance of urinary lipocalin-2 for discriminating SLE patients with nephritis from those without nephritis.	114

ABSTRACT

Objective: the aim of this study is to determine the role of urinary and serum lipocalin-2 as a biomarker in the systemic lupus erythematosus (SLE).

Methods: thirty patients with SLE were divided and selected into fifteen patients with lupus nephritis (LN), and fifteen SLE patients without LN. All patients were subjected to full history taking, full examination, complete urine analysis and detection of all the laboratory and radiological examination needed for SLE diagnosis. SLE Disease Activity Index (SLEDAI) score were evaluated to all SLE patients. Results were matched with fifteen control participants with normal urine analysis, all were age and sex matched.

Results: Urinary lipocalin-2 showed highly significant statistical difference in comparing all SLE patients and the controls ($p < 0.001$). The LN group showed higher mean levels of urinary lipocalin-2 than the compared groups ($p < 0.001$). Urinary lipocalin-2 correlated significantly with blood urea nitrogen, serum creatinine, 24/hr urine protein, total SLEDAI and the renal SLEDAI. No correlation was found between urinary lipocalin-2 and the extra-renal SLEDAI, disease duration, anti-dsDNA, C3 and C4. The levels of serum lipocalin-2 did not show significant statistical difference between all SLE patients and the control, and also no significant statistical difference between (LN) group, and the non-LN group. Also no correlation was found as regards the urinary and the serum lipocalin-2.

Conclusion: Urinary lipocalin-2 could be used as a biomarker of SLE disease activity. Serum lipocalin-2 did not prove its usage in the assessment of renal involvement in SLE.

Key Words: Systemic Lupus Erythematosus (SLE), Lupus nephritis (LN), Urinary and serum lipocalin-2.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease predominantly affecting women in the childbearing period (**Shankar and Behera 2014**). The majority of the pathology in SLE is related to deposits of immune complexes in various organs, which triggers complement and other mediators of inflammation (**Cojocaru et al., 2011**).

SLE is characterized by a very large spectrum of clinical manifestations accompanied by prototypic abnormalities of the immune system. While recent advances in therapeutic approaches have taken place, SLE still has a profound impact on the quality of life and life expectancy of affected persons (**Chizzolini et al., 2009**).

Renal involvement occurs in 40–70% of all SLE patients and is a major cause of morbidity and hospital admissions (**Bertsias et al., 2012**). Its clinical presentations are highly variable, ranging from mild asymptomatic proteinuria and/or hematuria to rapidly progressive uremia. Early diagnosis and prompt treatment may dramatically modify the course of renal disease and improve the long term survival (**Molino et al., 2009**). Approximately 10 to 30 % of patients with lupus nephritis progress to end-stage renal disease (ESRD) (**Bomback and Gerald, 2013**).

The accepted routine measures of assessing patients with SLE includes acute phase markers, erythrocyte sedimentation rate (ESR), C-reactive protein, plasma/serum complement component 3 (C3) and component 4 (C4) and presence of antibodies to double-stranded DNA (anti-dsDNA) (**Elwy et al., 2010**). Such markers help in a variety of ways, including early detection of flare, distinction between flare and chronic damage and monitoring response to therapy. However, improved new markers are required to assist clinicians in diagnosis of lupus patients. Among these new markers, lipocalin-2 is a promising one (**Adhya et al., 2011**).

The lipocalin protein family is a large group of mostly secreted soluble proteins that carrying small molecules to specific cells. Lipocalin-2, also known as neutrophil gelatinase-associated lipocalin (NGAL) is expressed in neutrophils and in low levels in the kidneys (**Sharifipour et al., 2013**).

NGAL has been evaluated as an early biomarker of acute kidney injury after cardiopulmonary bypass and kidney transplantation (**Abdallah E et al., 2013**). It is also a candidate biomarker for chronic kidney diseases, such as immunoglobulin a nephropathy, membranous and membranoproliferative glomerulonephritis (**Yang et al., 2012**). Based on these findings, Lipocalin-2 may be a potential biomarker for renal damage/inflammation in lupus nephritis.

AIM OF THE WORK

The aim of the present study is to assess serum and urinary lipocalin- 2 level in patients with Systemic lupus erythematosus (SLE) and its correlation to disease activity and lupus nephritis (LN).

SYSTEMIC LUPUS ERYTHEMATOSUS

Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by diverse multisystem involvement and the production of an array of autoantibodies. Clinical features in individual patients can be quite variable, ranging from mild joint and skin involvement to severe life-threatening internal organ disease **(Dall'Era and Wofsy, 2013)**.

Systemic lupus erythematosus (SLE) preferentially affects the vasculature, joints, skin, hematopoietic system, kidneys, brain and serosal surfaces **(Rahman & Isenberg, 2008)**. It predominantly targeting young women in their childbearing years and with the potential to cause significant physical disfigurement, morbidity and occasionally mortality **(Crow, 2013)**.

Although the specific cause of SLE is unknown, multiple factors are associated with the development of the disease, including genetic, racial, and environmental factors. Immune complexes form in the microvasculature, leads to complement activation and inflammation. Moreover, antibody-antigen complexes deposit on the basement membranes of skin and kidneys. In active SLE, this process has been confirmed based on the presence of complexes of nuclear antigens such as DNA,

immunoglobulins, and complement proteins at these sites. Serum antinuclear antibodies (ANAs) are found in virtually all individuals with active SLE, and antibodies to native double-stranded DNA (dsDNA) are relatively specific for the diagnosis of SLE **(Rahman and Isenberg, 2008)**.

Sociodemographic factors such as sex and race play an important role in the incidence of the disease, frequency of its manifestations, and therapeutic response **(Salgado and Herrera-Diaz, 2012)**.

Pathogenesis of SLE:

The pathogenesis of systemic lupus erythematosus (SLE) is complex. Target tissue damage is caused primarily by pathogenic autoantibodies and immune complexes. The immunologic abnormalities occur in a framework of interactions between multiple susceptibility genes, gender influences; and environmental stimuli, at least one of which ultraviolet [UV] light can induce apoptosis in dermal cells that results in presentation of RNA protein, DNA protein, and phospholipid self-antigens to the immune system **(Hahn and Tsao, 2008), figure (1)**.

Although genetic, environmental, and sex hormonal factors have been implicated in the pathogenesis of SLE, it is known that several cytokines, nitric oxide (NO), free radicals, a

deranged immune system, deficient antioxidant defenses, and toll-like receptors have a significant role both in the initiation and perpetuation of the inflammatory process observed **(Das, 2010)**. Once the inflammatory process is triggered, this leads to the production of a variety of proinflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor- α (TNF- α), interferons (IFNs), macrophage migration inhibitory factor (MIF), HMGB-1 (high-mobility group B1), and possibly a reduction in the elaboration of anti-inflammatory cytokines such as IL-10, IL-4, and transforming growth factor- β (TGF- β) **(Das, 2010)**.

This imbalance between the pro- and anti-inflammatory cytokines coupled with increased secretion of free radicals such as superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), inducible nitric oxide (iNO), and other reactive oxygen species (ROS) by activated monocytes, macrophages, polymorphonuclear leukocytes (PMNL), T-cells, Kupffer cells, glial cells in the brain, and other organ-specific reticuloendothelial cells would ultimately cause target tissue/organ damage seen in SLE **(Das, 2010)**.